Nivo + chemo vs chemo as first-line treatment for advanced GC/GEJC/EAC

(5:56)

Surgical outcomes from CheckMate 816: NIVO plus chemo vs chemo alone as neoadjuvant treatment fo...

(7:23)

CheckMate 649 biomarker analyses of NIVO + IPI vs chemo for patients with GC/GEJC/EAC

(6:31)

ATTRACTION-5: nivo + chemo as postoperative adju treatment for pathological stage III G/GEJ cancer

(1:11)

CheckMate 648: Nivolumab plus ipilimumab or NIVO plus chemo versus chemo as (1L) treatment for a...

(9:32)

NIVO + chemo vs chemo as 1L treatment for advanced GC/GEJC/EAC: 4 year yr follow-up of CheckMate 649

(2:26)

CheckMate 649: 1L nivo + chemotherapy improves OS

(6:54)

Cancer Immunotherapy with Nivolumab Plus Ipilimumab Vs. Chemotherapy: Insights from CheckMate 227

(2:44)

Nivo/Ipi vs. Chemo: Key Results from CheckMate 227 (BMIC-034)

(13:7)

Nivolumab chemotherapy combination treatment: CheckMate649 and ATTRACTION-4

(4:47)

Dr. O’Hara on Rationale for APX005M/Chemotherapy and Nivolumab in Pancreatic Cancer

(1:5)

ATTRACTION-5: Nivo plus chemotherapy as postoperative adjuvant treatment for pStage III G/GEJ cancer

(2:26)

CheckMate 9LA study: nivo + ipi in NSCLC

(7:16)

Nivolumab plus ipilimumab improves on chemo in previously untreated MSI-H/dMMR mCRC

(5:37)

CheckMate 649: nivolumab and chemotherapy or ipilimumab in GC/GEJC/EAC

(1:44)

#ESMO21 Highlights on nivo+ipi vs EXTREME in 1st-line high-risk SCCHN: The CheckMate 651 study

(3:9)

CheckMate 743: First-line nivolumab plus ipilimumab vs chemotherapy in patients with unresectabl...

(5:22)

CheckMate 648: NIVO + chemo or IPI vs chemo as 1L treatment for advanced ESCC

(2:10)

HCRN GU16-260: Nivolumab, Salvage Nivo/Ipi in Advanced Clear Cell RCC

(8:7)

NIVAHL: nivolumab and AVD in early-stage unfavorable HL

(3:4)